{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:50:54Z","timestamp":1792101054386,"version":"4.4.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013116","name":"Merz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013116","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.jns.2012.01.019","type":"journal-article","created":{"date-parts":[[2012,2,14]],"date-time":"2012-02-14T00:16:13Z","timestamp":1329178573000},"page":"9-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Botulinum toxins in the treatment of primary focal dystonias"],"prefix":"10.1016","volume":"316","author":[{"given":"Daniel","family":"Truong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jns.2012.01.019_bb0005","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/mds.22597","article-title":"Is this dystonia?","volume":"24","author":"Albanese","year":"2009","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.jns.2012.01.019_bb0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2010.03042.x","article-title":"EFNS guidelines on diagnosis and treatment of primary dystonias","volume":"18","author":"Albanese","year":"2011","journal-title":"Eur J Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.jns.2012.01.019_bb0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-1331.2010.03053.x","article-title":"The epidemiology of primary dystonia: current evidence and perspectives","volume":"17","author":"Defazio","year":"2010","journal-title":"Eur J Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.jns.2012.01.019_bb0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1468-1331.2010.03055.x","article-title":"The role of genes in causing dystonia","volume":"17","author":"Schmidt","year":"2010","journal-title":"Eur J Neurol"},{"issue":"13","key":"10.1016\/j.jns.2012.01.019_bb0025","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/mds.23225","article-title":"Genetic evidence for an association of the TOR1A locus with segmental\/focal dystonia","volume":"25","author":"Sharma","year":"2010","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"10.1016\/j.jns.2012.01.019_bb0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0733-8619(08)80003-5","article-title":"Epidemiology, clinical presentation, and diagnosis of cervical dystonia","volume":"26","author":"Stacy","year":"2008","journal-title":"Neurol Clin"},{"issue":"5","key":"10.1016\/j.jns.2012.01.019_bb0035","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1468-1331.2006.01537.x","article-title":"A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS\/MDS-ES Task Force","volume":"13","author":"Albanese","year":"2006","journal-title":"Eur J Neurol"},{"issue":"23","key":"10.1016\/j.jns.2012.01.019_bb0040","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1080\/01421590701568262","article-title":"Botulinum toxin treatment of axial and cervical dystonia","volume":"29","author":"Benecke","year":"2007","journal-title":"Disabil Rehabil"},{"issue":"19","key":"10.1016\/j.jns.2012.01.019_bb0045","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","article-title":"Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2012.01.019_bb0050","series-title":"Package insert, BOTOX (Botulinum toxin type A purified neurotoxin complex)","author":"Allergan Inc","year":"2000"},{"key":"10.1016\/j.jns.2012.01.019_bb0055","series-title":"Dysport prescribing information","author":"Ipsen Biopharm Ltd","year":"2009"},{"key":"10.1016\/j.jns.2012.01.019_bb0060","series-title":"Xeomin prescribing information","author":"Merz Pharmaceuticals, LLC","year":"2010"},{"key":"10.1016\/j.jns.2012.01.019_bb0065","series-title":"Myobloc prescribing information","author":"Solstice Neurosciences Inc","year":"2010"},{"key":"10.1016\/j.jns.2012.01.019_bb0070","author":"U.S. Food and Drug Administration"},{"issue":"23","key":"10.1016\/j.jns.2012.01.019_bb0075","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1080\/09638280701568296","article-title":"Pharmacology of therapeutic botulinum toxin preparations","volume":"29","author":"Dressler","year":"2007","journal-title":"Disabil Rehabil"},{"issue":"5","key":"10.1016\/j.jns.2012.01.019_bb0080","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.toxicon.2009.03.010","article-title":"Xeomin is free from complexing proteins","volume":"54","author":"Frevert","year":"2009","journal-title":"Toxicon"},{"issue":"1","key":"10.1016\/j.jns.2012.01.019_bb0085","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jama.2010.1937","article-title":"Terminology for preparations of botulinum neurotoxins: what a difference a name makes","volume":"305","author":"Albanese","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jns.2012.01.019_bb0090","article-title":"Neurotoxin therapy: a closer look at the four options","author":"Gollomp","year":"2011","journal-title":"Pract Neurol"},{"issue":"4","key":"10.1016\/j.jns.2012.01.019_bb0095","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1017\/S031716710003540X","article-title":"A pilot study on the use of botulinum toxin in spasmodic torticollis","volume":"12","author":"Tsui","year":"1985","journal-title":"Can J Neurol Sci"},{"issue":"8501","key":"10.1016\/j.jns.2012.01.019_bb0100","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(86)92070-2","article-title":"Double-blind study of botulinum toxin in spasmodic torticollis","volume":"2","author":"Tsui","year":"1986","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jns.2012.01.019_bb0105","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/archopht.1985.01050030043017","article-title":"Botulinum A toxin injection as a treatment for blepharospasm","volume":"103","author":"Scott","year":"1985","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.jns.2012.01.019_bb0110","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00702-007-0831-4","article-title":"The treatment of cervical dystonia with botulinum toxins","volume":"115","author":"Comella","year":"2008","journal-title":"J Neural Transm"},{"issue":"9","key":"10.1016\/j.jns.2012.01.019_bb0115","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1468-1331.2004.00867.x","article-title":"Guidance for the preparation of neurological management guidelines by EFNS scientific task forces \u2014 revised recommendations 2004","volume":"11","author":"Brainin","year":"2004","journal-title":"Eur J Neurol"},{"issue":"4","key":"10.1016\/j.jns.2012.01.019_bb0120","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.46.4.1066","article-title":"Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial","volume":"46","author":"Brans","year":"1996","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jns.2012.01.019_bb0125","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.53.7.1439","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia","volume":"53","author":"Brashear","year":"1999","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jns.2012.01.019_bb0130","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia","volume":"53","author":"Brin","year":"1999","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jns.2012.01.019_bb0135","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1212\/WNL.40.8.1213","article-title":"Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis","volume":"40","author":"Greene","year":"1990","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2012.01.019_bb0140","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1212\/WNL.49.3.701","article-title":"Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia","volume":"49","author":"Lew","year":"1997","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2012.01.019_bb0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp.64.1.13","article-title":"What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group","volume":"64","author":"Poewe","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.jns.2012.01.019_bb0150","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2010.03.002","article-title":"Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia","volume":"16","author":"Truong","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"10.1016\/j.jns.2012.01.019_bb0155","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20403","article-title":"Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study","volume":"20","author":"Truong","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.jns.2012.01.019_bb0160","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1113\/jphysiol.1962.sp006843","article-title":"Influence of nerve-ending activity and of drugs on the rate of paralysis of rat diaphragm preparations by Cl. botulinum type A toxin","volume":"160","author":"Hughes","year":"1962","journal-title":"J Physiol"},{"issue":"3","key":"10.1016\/j.jns.2012.01.019_bb0165","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1017\/S0012162203000380","article-title":"Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis","volume":"45","author":"Kim","year":"2003","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"10.1016\/j.jns.2012.01.019_bb0170","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/mds.870120115","article-title":"The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humans","volume":"12","author":"Eleopra","year":"1997","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.jns.2012.01.019_bb0175","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/mds.20395","article-title":"Nerve stimulation boosts botulinum toxin action in spasticity","volume":"20","author":"Frasson","year":"2005","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.jns.2012.01.019_bb0180","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1191\/026921598668275996","article-title":"Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial","volume":"12","author":"Hesse","year":"1998","journal-title":"Clin Rehabil"},{"issue":"4","key":"10.1016\/j.jns.2012.01.019_bb0185","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/mds.870020402","article-title":"Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm","volume":"2","author":"Brin","year":"1987","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.jns.2012.01.019_bb0190","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1212\/WNL.39.1.80","article-title":"Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis","volume":"39","author":"Gelb","year":"1989","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2012.01.019_bb0195","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1212\/WNL.40.2.277","article-title":"Botulinum toxin injections for cervical dystonia","volume":"40","author":"Jankovic","year":"1990","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2012.01.019_bb0200","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/bjo.71.9.664","article-title":"Long-term results of treatment of idiopathic blepharospasm with botulinum toxin injections","volume":"71","author":"Elston","year":"1987","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.jns.2012.01.019_bb0205","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","article-title":"Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm","volume":"113","author":"Roggenk\u00e4mper","year":"2006","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jns.2012.01.019_bb0210","first-page":"507","article-title":"Practical manual of physical medicine and rehabilitation","author":"Tan","year":"2006"},{"issue":"12","key":"10.1016\/j.jns.2012.01.019_bb0215","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s004150170028","volume":"248","author":"Wissel","year":"2001","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.jns.2012.01.019_bb0220","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s004150050345","article-title":"Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group","volume":"246","author":"Kessler","year":"1999","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.jns.2012.01.019_bb0225","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.parkreldis.2007.11.003","article-title":"Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial","volume":"14","author":"Truong","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"10.1016\/j.jns.2012.01.019_bb0230","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jnnp.64.1.6","article-title":"A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia","volume":"64","author":"Odergren","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2012.01.019_bb0235","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00941758","article-title":"Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm","volume":"235","author":"N\u00fcssgens","year":"1997","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.jns.2012.01.019_bb0240","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12640-009-9023-3","article-title":"Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs","volume":"15","author":"Bentivoglio","year":"2009","journal-title":"Neurotox Res"},{"issue":"4","key":"10.1016\/j.jns.2012.01.019_bb0245","first-page":"459","article-title":"Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia","volume":"72","author":"Ranoux","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.jns.2012.01.019_bb0250","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1185\/030079905X36396","article-title":"Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm","volume":"21","author":"Bihari","year":"2005","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"10.1016\/j.jns.2012.01.019_bb0255","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","article-title":"A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia","volume":"64","author":"Benecke","year":"2005","journal-title":"Neurology"},{"issue":"Suppl 3","key":"10.1016\/j.jns.2012.01.019_bb0260","first-page":"A344","article-title":"Clinical efficacy in focal dystonia and overall tolerability of NT 201 (botulinum neurotoxin free from complexing proteins) [abstract]","volume":"72","author":"Grafe","year":"2009","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jns.2012.01.019_bb0265","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00003495-200767050-00003","article-title":"Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia","volume":"67","author":"Jost","year":"2007","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.jns.2012.01.019_bb0270","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/jama.295.10.1147","article-title":"Quality of reporting of noninferiority and equivalence randomized trials","volume":"295","author":"Le Henanff","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jns.2012.01.019_bb0275","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1212\/WNL.37.4.616","article-title":"Botulinum A toxin for cranial\u2013cervical dystonia: a double-blind, placebo-controlled study","volume":"37","author":"Jankovic","year":"1987","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1016\/j.jns.2012.01.019_bb0280","first-page":"S77","article-title":"The Blepharospasm Disability Index (BSDI) for the assessment of functional health in focal dystonia","volume":"113","author":"Goertelmeyer","year":"2002","journal-title":"Clin Neurophysiol"},{"issue":"1","key":"10.1016\/j.jns.2012.01.019_bb0285","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0885-3924(00)00146-9","article-title":"Management of spasticity associated pain with botulinum toxin A","volume":"20","author":"Wissel","year":"2000","journal-title":"J Pain Symptom Manage"},{"issue":"Suppl 3","key":"10.1016\/j.jns.2012.01.019_bb0290","first-page":"A345","article-title":"Efficacy and safety of NT 201 (neurotoxin free from complexing proteins) in cervical dystonia","volume":"72","author":"Comella","year":"2009","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1016\/j.jns.2012.01.019_bb0295","first-page":"S92","article-title":"Efficacy and safety of NT 201: botulinum neurotoxin type A free from complexing proteins, in treatment-naive cervical dystonia patients [abstract]","volume":"24","author":"Grafe","year":"2009","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"10.1016\/j.jns.2012.01.019_bb0300","first-page":"S92","article-title":"Efficacy and safety of NT 201: botulinum neurotoxin type A free from complexing proteins, in treatment-naive cervial dystonia patients [abstract]","volume":"24","author":"Grafe","year":"2009","journal-title":"Mov Disord"},{"issue":"Suppl 2","key":"10.1016\/j.jns.2012.01.019_bb0305","first-page":"A88","article-title":"Safety and efficacy of repeated NT 201 (botulinum neurotoxin type A free from complexing proteins) injections of patients with cervical dystonia: a first long-term safety analysis [abstract]","volume":"74","author":"Grafe","year":"2010","journal-title":"Neurology"},{"issue":"Suppl 3","key":"10.1016\/j.jns.2012.01.019_bb0310","first-page":"A346","article-title":"Efficacy and safety of NT 201 (botulinum neurotoxin free from complexing proteins) in blepharospasm","volume":"72","author":"Jankovic","year":"2009","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jns.2012.01.019_bb0315","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1212\/WNL.45.11.2109","article-title":"Botulinum toxin type B in the treatment of cervical dystonia: a pilot study","volume":"45","author":"Tsui","year":"1995","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2012.01.019_bb0320","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.21724","article-title":"Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial","volume":"23","author":"Pappert","year":"2008","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.jns.2012.01.019_bb0325","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","article-title":"Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia","volume":"65","author":"Comella","year":"2005","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jns.2012.01.019_bb0330","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1212\/01.wnl.0000174433.76707.8c","article-title":"Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial","volume":"65","author":"Tintner","year":"2005","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jns.2012.01.019_bb0335","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s00415-005-0774-3","article-title":"Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure","volume":"252","author":"Dressler","year":"2005","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.jns.2012.01.019_bb0340","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/WNF.0b013e3181c46f48","article-title":"A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia","volume":"33","author":"Quagliato","year":"2010","journal-title":"Clin Neuropharmacol"},{"issue":"9","key":"10.1016\/j.jns.2012.01.019_bb0345","first-page":"794","article-title":"Comparison of Botox with a Chinese type A botulinum toxin","volume":"113","author":"Tang","year":"2000","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"10.1016\/j.jns.2012.01.019_bb0350","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/WNF.0b013e3181c46f61","article-title":"Prospective, randomized, double-blind study, comparing botulinum toxins type a botox and prosigne for blepharospasm and hemifacial spasm treatment","volume":"33","author":"Quagliato","year":"2010","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1016\/j.jns.2012.01.019_bb0355","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/01.WNF.0000236771.77021.3C","article-title":"A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm","volume":"30","author":"Rieder","year":"2007","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.jns.2012.01.019_bb0360","series-title":"Neuronox prescribing information","author":"Medy-Tox Inc","year":"2006"},{"issue":"3","key":"10.1016\/j.jns.2012.01.019_bb0365","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3341\/kjo.2009.23.3.137","article-title":"Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm","volume":"23","author":"Yoon","year":"2009","journal-title":"Korean J Ophthalmol"},{"issue":"Suppl 1","key":"10.1016\/j.jns.2012.01.019_bb0370","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1468-1331.2010.03058.x","article-title":"Botulinum toxin for treatment of dystonia","volume":"17","author":"Dressler","year":"2010","journal-title":"Eur J Neurol"},{"issue":"4","key":"10.1016\/j.jns.2012.01.019_bb0375","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1212\/WNL.42.4.878","article-title":"Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance","volume":"42","author":"Comella","year":"1992","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jns.2012.01.019_bb0380","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1185\/030079904125003962","article-title":"Safety of botulinum toxin type A: a systematic review and meta-analysis","volume":"20","author":"Naumann","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.1016\/j.jns.2012.01.019_bb0385","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/mds.20376","article-title":"Long-term botulinum toxin efficacy, safety, and immunogenicity","volume":"20","author":"Mejia","year":"2005","journal-title":"Mov Disord"},{"issue":"Suppl 2","key":"10.1016\/j.jns.2012.01.019_bb0390","first-page":"S232","article-title":"CD-PROBE (cervical dystonia patient registry for observation of BOTOX\u00ae efficacy) \u2014 preliminary safety data [abstract]","volume":"25","author":"Charles","year":"2010","journal-title":"Mov Disord"},{"issue":"Suppl 2","key":"10.1016\/j.jns.2012.01.019_bb0395","first-page":"S229","article-title":"CD-PROBE (cervical dystonia patient registry for observation of BOTOX\u00ae efficacy) \u2014 CD impact on quality of life (QOL) and patient reported outcomes (PRO) [abstract]","volume":"25","author":"Kurth","year":"2010","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.jns.2012.01.019_bb0400","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1212\/01.WNL.0000142962.11881.26","article-title":"Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58)","volume":"63","author":"Cano","year":"2004","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2012.01.019_bb0405","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/014107689208500906","article-title":"Botulinum toxin treatment of spasmodic torticollis","volume":"85","author":"Anderson","year":"1992","journal-title":"J R Soc Med"},{"issue":"3","key":"10.1016\/j.jns.2012.01.019_bb0410","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1001\/archneur.59.3.418","article-title":"Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study","volume":"59","author":"Defazio","year":"2002","journal-title":"Arch Neurol"},{"issue":"Suppl 2","key":"10.1016\/j.jns.2012.01.019_bb0415","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-1331.2009.02877.x","article-title":"Routine use of Xeomin in patients previously treated with Botox: long term results","volume":"16","author":"Dressler","year":"2009","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1016\/j.jns.2012.01.019_bb0420","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/mds.10252","article-title":"Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period","volume":"17","author":"Hsiung","year":"2002","journal-title":"Mov Disord"},{"issue":"10","key":"10.1016\/j.jns.2012.01.019_bb0425","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","article-title":"Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay","volume":"23","author":"Brin","year":"2008","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.jns.2012.01.019_bb0430","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00415-010-5880-1","article-title":"Evolution of dose and response to botulinum toxin A in cervical dystonia: a multicenter study","volume":"258","author":"Garcia-Ruiz","year":"2011","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.jns.2012.01.019_bb0435","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","article-title":"Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia","volume":"60","author":"Jankovic","year":"2003","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2012.01.019_bb0440","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/mds.20290","article-title":"Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia","volume":"20","author":"Berman","year":"2005","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.jns.2012.01.019_bb0445","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/mds.20531","article-title":"Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia","volume":"20","author":"Factor","year":"2005","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.jns.2012.01.019_bb0450","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/01.wnl.0000252932.71306.89","article-title":"Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia","volume":"68","author":"Hung","year":"2007","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2012.01.019_bb0455","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneurol.2009.20","article-title":"Deep brain stimulation for primary generalized dystonia: long-term outcomes","volume":"66","author":"Isaias","year":"2009","journal-title":"Arch Neurol"},{"issue":"Suppl 2","key":"10.1016\/j.jns.2012.01.019_bb0460","first-page":"207","article-title":"Selective peripheral denervation for spasmodic torticollis: 13-year experience with 155 patients","volume":"97","author":"Braun","year":"2002","journal-title":"J Neurosurg"},{"issue":"6","key":"10.1016\/j.jns.2012.01.019_bb0465","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.3171\/jns.2003.98.6.1247","article-title":"Selective peripheral denervation for the treatment of intractable spasmodic torticollis: experience with 168 patients at the Mayo Clinic","volume":"98","author":"Cohen-Gadol","year":"2003","journal-title":"J Neurosurg"},{"issue":"4","key":"10.1016\/j.jns.2012.01.019_bb0470","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/jnnp.65.4.472","article-title":"Outcome of selective ramisectomy for botulinum toxin resistant torticollis","volume":"65","author":"Ford","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1016\/j.jns.2012.01.019_bb0475","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/mds.21051","article-title":"Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test","volume":"21","author":"Cordivari","year":"2006","journal-title":"Mov Disord"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X12000202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X12000202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:41:39Z","timestamp":1758382899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X12000202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":95,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0022510X12000202"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2012.01.019","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Botulinum toxins in the treatment of primary focal dystonias","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2012.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}